Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

Alpha Tau CEO Uzi Sofer: "Tolmar is a well-established company in the field of urology in the US. We decided to grant exclusivity for one of our most promising but least advanced indications. In the ...

Johnson & Johnson (J&J) has announced results from the final analysis of the phase 3 PROTEUS study showing that Erleada ...

Early-stage trials of a new drug for advanced prostate cancer have yielded "remarkable" results, according to medical experts. This innovative treatment, an immunotherapy designed to harness the ...

While prostate cancer affects one in eight men, early detection and advanced treatment options mean patients are living longer, healthier lives after diagnosis, according to the American Cancer ...

Men newly diagnosed with prostate cancer often turn first to testosterone-depleting therapies, since male hormones help prostate tumors grow. But, those therapies almost always fail over time as the ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

The US Food and Drug Administration (FDA) on Wednesday released draft guidance to help sponsors establish the effectiveness and safety of gonadotropin-releasing hormone (GnRH) analogues for treating ...

Former President Joe Biden is facing an “aggressive” case of Stage 4 prostate cancer, his office announced over the weekend in a statement. “Cancer touches us all. Like so many of you, Jill and I have ...